Sugi Predict

Sugi Predict / Compounds / SCHEMBL504156

SCHEMBL504156

SCHEMBL504156

CCOc1cc(C(=O)O)cc(OCC)c1OCC

nearest known ligand 0.70

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.70
▸ HTT P42858 2/20 0.60
▸ POLB P06746 1/20 0.60
▸ ALOX15 P16050 1/20 0.60
▸ GAA P10253 2/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ LMNA P02545 1/20 0.56
▸ GLA P06280 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.54
▸ NPC1 O15118 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9046507 0.89 TSHR (0.65) TSHRHTTPOLBALOX15MEN1
SCHEMBL8638411 0.89 TPMT (0.66) TSHRHTTPOLBALOX15MEN1
SCHEMBL28501635 0.88 TSHR (0.60) TSHRHTTPOLBALOX15GAA
SCHEMBL1420745 0.88 HTT (0.78) TSHRHTTPOLBALOX15GAA
SCHEMBL19970621 0.88 TSHR (0.56) TSHRHTTPOLBALOX15GAA
SCHEMBL19970626 0.86 TSHR (0.54) TSHRHTTPOLBALOX15GAA
SCHEMBL17303480 0.86 TSHR (0.72) TSHRHTTGAASMN1; SMN2MEN1
SCHEMBL6990203 0.85 TSHR (0.66) TSHRHTTPOLBALOX15MEN1
SCHEMBL19970638 0.85 TSHR (0.53) TSHRHTTPOLBALOX15GAA
SCHEMBL1515929 0.84 TSHR (0.59) TSHRHTTPOLBALOX15GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025202864-A1 ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER iTeos Belgium SA (BE) 2025-10-02 — — WO claimed
WO-2025126110-A1 ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES iTeos Belgium SA (BE) 2025-06-19 — — WO claimed
WO-2025104613-A1 ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS iTeos Belgium SA (BE) 2025-05-22 — — WO claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN claimed
CN-117327171-B Modified recombinant humanized collagen and application thereof in vaginal dressing 江苏亨瑞生物医药科技有限公司 2024-03-12 — — CN claimed
CN-117327171-A Modified recombinant humanized collagen and application thereof in vaginal dressing 江苏亨瑞生物医药科技有限公司 2024-01-02 — — CN claimed
CN-116535365-A Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer ITEOS比利时公司 2023-08-04 — — CN claimed
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 — — US claimed
EP-4132933-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-02-15 — — EP claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
WO-1999005319-A9 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE INC (US) 1999-06-17 — — WO claimed
WO-1999005319-A2 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE, INC. (US) 1999-02-04 — — WO claimed
EP-0868535-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES Rapigene, Inc. (US) 1998-10-07 — — EP claimed
EP-0850320-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL DARWIN MOLECULAR CORPORATION (US) 1998-07-01 — — EP claimed
US-5686633-A PHOTOSTABILIZERS CIBA SPECIALTY CHEMICALS CORPORATION (US) 1997-11-11 — — US claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES — 1997-10-09 — — WO claimed
US-5663029-A DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS XEROX CORPORATION (US) 1997-09-02 — — US claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 — — WO claimed
WO-1997027327-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL RAPIGENE, INC. (US) 1997-07-31 — — WO claimed
EP-0161499-B1 PROCESS FOR PREPARATION OF AMINOPHTHALIDEISOQUINOLINES MITSUBISHI KASEI CORPORATION (JP) 1988-07-27 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD1, SLC29A1, ENTPD5 TSHR 778/4885HTT 2936/4885POLB 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.